Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-04-25 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2021年内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report". It is issued by a certified public accounting firm and addresses the internal control effectiveness related to the financial statements as of December 31, 2021. The report includes detailed descriptions of the internal control system, evaluation criteria for control deficiencies, and a self-assessment by the company. The document is a standalone audit-related report focusing on internal control over financial reporting, not a full annual report or financial statement. It is not a brief announcement or a certification letter but a comprehensive assurance report on internal controls. This matches the definition of an Audit Report / Information (AR). The document length (10,292 characters) supports it being a full report rather than a short announcement. FY 2021
2022-04-25 Chinese
2021年募集资金年度存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed audit report issued by China Audit Asia Pacific Certified Public Accountants LLP regarding the annual deposit and actual use of raised funds by Beijing Nuosiland Biotechnology Co., Ltd. It references specific regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange, and it includes detailed financial data about the raised funds, their management, usage, and compliance with regulations. The document is titled as a "鉴证报告" (verification or assurance report) on the annual deposit and use of raised funds, which is a specialized audit report rather than a full annual report or earnings release. It contains substantive financial data and audit opinions related to the use of capital raised by the company. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit report focusing on a specific aspect of the company's financials (fundraising usage and compliance). The document length (15,000 characters) and content confirm it is not a mere announcement or certification but a full audit report. FY 2021
2022-04-25 Chinese
2021年度控股股东、实际控制人及其关联方资金占用专项说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by China Audit Asia Pacific Certified Public Accountants LLP regarding the 2021 fiscal year. It specifically addresses the issue of funds occupied by the controlling shareholders, actual controllers, and their related parties of Beijing Northland Biotech Co., Ltd. The document includes detailed tables summarizing the fund occupation and explanations in compliance with the Beijing Stock Exchange listing rules. It is a standalone audit report focusing on a specific issue (fund occupation by related parties) rather than a full annual report or general audit report. The presence of audit firm details, audit opinion references, and the nature of the report as a "专项审核报告" (special audit report) confirms it is an Audit Report / Information filing. The document length (8484 characters) and content confirm it is not a mere announcement or certification but a substantive audit report. Therefore, the correct classification is AR (Audit Report / Information) with high confidence. FY 2021
2022-04-25 Chinese
拟修订公司章程公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding proposed amendments to the company's Articles of Association (公司章程). It includes extensive legal and regulatory references, detailed clause revisions, and governance-related content. The document does not contain financial statements, audit opinions, or earnings data. It is not a report of financial results or an announcement of voting results. Instead, it is a formal disclosure about governance documents and their revisions, which aligns with governance information filings. The length and detail confirm it is the actual document, not a brief announcement or notice. Therefore, the document fits best under Governance Information (CGR).
2022-04-25 Chinese
董事会议事规则
Governance Information Classification · 95% confidence The document is titled "北京诺思兰德生物技术股份有限公司董事会制度" which translates to "Beijing Northland Biotechnology Co., Ltd. Board of Directors System." It details the rules, procedures, and responsibilities of the company's board of directors, including meeting protocols, voting procedures, and board powers. There is no financial data, audit information, or report of financial results. The document is a governance document outlining internal rules and board structure. It is not an announcement or a brief notice but a full detailed governance framework. Therefore, it fits the category of Governance Information (CGR). The document length (7986 characters) supports it being a full governance document rather than a short announcement.
2022-04-25 Chinese
公司章程（草案）
Governance Information Classification · 95% confidence The document is titled as the "Articles of Association (Draft)" of Beijing Northland Biotech Co., Ltd. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, share issuance, share transfer, shareholder meetings, and other governance matters. The content is focused on the company's internal rules, governance framework, and procedures, including shareholder meetings and board responsibilities. There is no indication of financial statements, audit results, earnings data, or announcements of voting results. The document is a comprehensive governance document outlining the company's articles of association, which is a governance information report. Therefore, the appropriate classification is Governance Information (CGR).
2022-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.